Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 7/2007

01-07-2007 | Letter to the Editor

Imatinib-induced Stevens–Johnson syndrome: recurrence after re-challenge with a lower dose

Authors: Manoranjan Mahapatra, Pravas Mishra, Rajat Kumar

Published in: Annals of Hematology | Issue 7/2007

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P et al (2003) Adverse reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 48:201–206PubMedCrossRef
2.
3.
Keechilat P, Mathew T (2005) Imatinib induced Stevens–Johnson syndrome: lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol 71(4):288–289CrossRef
4.
Vidal D, Puig L, Sureda A, Alomar A (2002) STI571-induced Stevens–Johnson syndrome. Br J Haematol 119:274–275PubMedCrossRef
5.
Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS et al (2002) Stevens–Johnson syndrome after treatment with STI571: a case report. Br J Haematol 117:620–622PubMedCrossRef
6.
Rule SA, O’Brien SG, Crossman LC (2002) Managing cutaneous reactions to imatinib therapy. Blood 100:3434–3435PubMedCrossRef
7.
Shah N, Pasquini R, Rousselet P, Jootar S, Holowiecki J, Countouriotis A, Dejardin D, Hughes T, Druker BJ (2006) Dasatanib vs escalated dose of imatinib in patients with chronic phase chronic myeloid leukemia resistant to imatinib: results of the CA180-017 START-R randomized study. Blood 108:167aCrossRef
Metadata
Title
Imatinib-induced Stevens–Johnson syndrome: recurrence after re-challenge with a lower dose
Authors
Manoranjan Mahapatra
Pravas Mishra
Rajat Kumar
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 7/2007
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-007-0265-y

Other articles of this Issue 7/2007

Annals of Hematology 7/2007 Go to the issue

Erratum

High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage

Original Article

Discrimination indices as screening tests for β-thalassemic trait

Original Article

Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature

Original Article

A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells

Letter to the Editor

Profuse erythema multiforme induced by chlorambucil

Original Article

Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits